Status:
COMPLETED
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
Lead Sponsor:
R&D Cardiologie
Conditions:
Anticoagulants
Platelet Aggregation Inhibitors
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding ...
Detailed Description
Chronic oral antithrombotic treatment is necessary in patients with mechanical heart valves and in the majority of patients with atrial fibrillation. When these patients have to undergo Percutaneous C...
Eligibility Criteria
Inclusion
- Patients is on oral anticoagulation therapy and this will be continued throughout the period of 1 year-and deployment of at least 1 coronary stent (bare metal stent (BMS) or drug eluting stent (DES)). -age of more than 18 years
Exclusion
- cardiogenic shock,
- contra-indication for aspirin or clopidogrel
- allergy to aspirin or clopidogrel,
- documented peptic ulcer disease within the previous six months,
- pregnancy and
- previous intracerebral haemorrhage or
- significant thrombocytopenia (platelet count \< 50x10 9/L).
- major bleeding according to timi criteria within the past 12 months
- age \> 80 years
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
573 Patients enrolled
Trial Details
Trial ID
NCT00769938
Start Date
December 1 2008
End Date
August 1 2012
Last Update
January 15 2013
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ KU Leuven
Leuven, Leuven, Belgium
2
OLV Aalst
Aalst, Belgium
3
UZ Antwerpen
Antwerp, Belgium
4
ZOL
Genk, Belgium